Development of non-ATP competitive chemical biology probes to elucidate mechanisms of PLK1 activation and stability.
开发非 ATP 竞争性化学生物学探针以阐明 PLK1 激活和稳定性的机制。
基本信息
- 批准号:10290769
- 负责人:
- 金额:$ 20.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAllosteric RegulationBindingBinding SitesBiologyBiophysicsCell CycleCellsChemicalsClinicalDataDevelopmentDimerizationDoseDrug TargetingHydrophobicityLigand BindingLigandsLightMalignant NeoplasmsMeasuresMediatingMitosisMitoticMolecularMolecular ConformationNamesPLK1 genePharmaceutical ChemistryPhosphorylationPhosphothreoninePhosphotransferasesPlayPolo-Box DomainProteinsRegulationRoleSeriesSiteStructureSumoylation PathwayTPT1 geneTailTherapeuticTimeUbiquitinationWorkantitumor drugbasecancer cellcell growth regulationclinical developmentdesigndimerevent cycleexperimental studyimprovedinhibitor/antagonistinorganic phosphateinsightmonomermulticatalytic endopeptidase complexnovelpolo-like kinase kinase 1preclinical developmentpreventprostate cancer cell linerecruittumorubiquitin-protein ligase
项目摘要
Polo-like kinase 1 (PLK1) is a central player in regulating entry into and progression through
mitosis. Many studies have validated PLK1 as an anti-tumor drug target, and its inhibition is
potently anti-proliferative to cancer cells. We have discovered a series of compounds that bind
potently to the polo-box domain of PLK1 named abbapolins through a cryptic pocket and which
induce proteasome mediated degradation of the PLK1 protein in a dose dependent manner
without the addition of a ligand to recruit an E3 ligase to promote ubiquitination (PROTAC
approach). The abbapolins are also able to inhibit the phosphorylation of a PLK1 specific marker
while potently inhibiting the proliferation of prostate cancer cell lines. As a result of these exciting
observations, we propose to further develop these inhibitors as potent PBD inhibitors and
degraders of PLK1 while using them as chemical biology probes to provide new insights the
regulation of PLK1 activity through conformational change, substrate recognition and proteasomal
stability. Our experiments will therefore shed new light into the regulation of PLK1 at the cellular
level while generating novel data on the molecular determinants and features important for
inhibition. In turn this may provide understanding of the factors contributing to the lack of clinical
activity for the ATP competitive inhibitors of the PLK mitotic kinases while laying the groundwork
for preclinical and clinical development the abbapolins as cancer therapeutics with a unique
mechanism of action.
Polo样激酶1(PLK 1)是调节进入和进展的核心参与者,
分裂。许多研究已经证实PLK 1是一个抗肿瘤药物靶点,其抑制作用是通过抑制PLK 1的表达来实现的。
对癌细胞有很强的抗增殖作用。我们发现了一系列化合物
通过一个神秘的口袋,有效地连接到PLK 1的polo-box结构域,称为abbapolins,
以剂量依赖性方式诱导蛋白酶体介导的PLK 1蛋白降解
不添加配体以募集E3连接酶来促进泛素化(PROTAC
方法)。阿巴布林还能够抑制PLK 1特异性标志物的磷酸化
同时有效地抑制前列腺癌细胞系的增殖。由于这些令人兴奋的
观察,我们建议进一步开发这些抑制剂作为有效的PBD抑制剂,
PLK 1的降解剂,同时将它们用作化学生物学探针,
通过构象变化、底物识别和蛋白酶体调节PLK 1活性
稳定因此,我们的实验将为PLK 1在细胞内的调节提供新的线索。
水平,同时产生新的数据的分子决定因素和功能的重要
抑制作用反过来,这可以提供对导致缺乏临床治疗的因素的理解。
活性的ATP竞争性抑制剂的PLK有丝分裂激酶,同时奠定基础
对于临床前和临床开发,abbapolins作为癌症治疗剂具有独特的
作用机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Campbell McInnes其他文献
Campbell McInnes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Campbell McInnes', 18)}}的其他基金
Development of non-ATP competitive chemical biology probes to elucidate mechanisms of PLK1 activation and stability.
开发非 ATP 竞争性化学生物学探针以阐明 PLK1 激活和稳定性的机制。
- 批准号:
10437922 - 财政年份:2021
- 资助金额:
$ 20.9万 - 项目类别:
Novel Chemical Biology Probes based on Selective Inhibitors of the Polo-Box Domain of PLK1
基于 PLK1 Polo-Box 结构域选择性抑制剂的新型化学生物学探针
- 批准号:
9517781 - 财政年份:2017
- 资助金额:
$ 20.9万 - 项目类别:
Polo-box PLK1 Inhibitors Target Tumors Resistant to ATP Competitive Compounds
Polo-box PLK1 抑制剂靶向对 ATP 竞争性化合物具有抗性的肿瘤
- 批准号:
9347798 - 财政年份:2017
- 资助金额:
$ 20.9万 - 项目类别:
Novel Chemical Biology Probes based on Selective Inhibitors of the Polo-Box Domain of PLK1
基于 PLK1 Polo-Box 结构域选择性抑制剂的新型化学生物学探针
- 批准号:
9378823 - 财政年份:2017
- 资助金额:
$ 20.9万 - 项目类别:
Inhibitors of B-raf through the Dimerization Interface
通过二聚化界面的 B-raf 抑制剂
- 批准号:
9024977 - 财政年份:2016
- 资助金额:
$ 20.9万 - 项目类别:
Inhibitors of B-raf through the Dimerization Interface
通过二聚化界面的 B-raf 抑制剂
- 批准号:
9212791 - 财政年份:2016
- 资助金额:
$ 20.9万 - 项目类别:
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
细胞周期蛋白依赖性激酶的非 ATP 竞争性抑制剂作为癌症治疗药物
- 批准号:
8782372 - 财政年份:2014
- 资助金额:
$ 20.9万 - 项目类别:
相似海外基金
Molecular insights into the allosteric regulation of opioid receptors
阿片受体变构调节的分子见解
- 批准号:
DE240100931 - 财政年份:2024
- 资助金额:
$ 20.9万 - 项目类别:
Discovery Early Career Researcher Award
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1
赖氨酸降解的变构调节作为 1 型戊二酸尿症的一种新的病理生理机制
- 批准号:
10720740 - 财政年份:2023
- 资助金额:
$ 20.9万 - 项目类别:
Elucidating the Mechanism for Allosteric Regulation of SIRT1 through the N-terminal Region
阐明 SIRT1 通过 N 末端区域变构调节的机制
- 批准号:
10627735 - 财政年份:2023
- 资助金额:
$ 20.9万 - 项目类别:
Allosteric Regulation of Actin Capping Protein: Mechanism and Significance
肌动蛋白加帽蛋白的变构调节:机制和意义
- 批准号:
10330809 - 财政年份:2022
- 资助金额:
$ 20.9万 - 项目类别:
Allosteric Regulation of Actin Capping Protein: Mechanism and Significance
肌动蛋白加帽蛋白的变构调节:机制和意义
- 批准号:
10797746 - 财政年份:2022
- 资助金额:
$ 20.9万 - 项目类别:
Allosteric Regulation of Actin Capping Protein: Mechanism and Significance
肌动蛋白加帽蛋白的变构调节:机制和意义
- 批准号:
10552651 - 财政年份:2022
- 资助金额:
$ 20.9万 - 项目类别:
Structural and functional studies of allosteric regulation of metabolic enzymes
代谢酶变构调节的结构和功能研究
- 批准号:
RGPIN-2020-04281 - 财政年份:2022
- 资助金额:
$ 20.9万 - 项目类别:
Discovery Grants Program - Individual
Allosteric regulation of human cystathionine beta-synthase
人胱硫醚β-合酶的变构调节
- 批准号:
10602404 - 财政年份:2022
- 资助金额:
$ 20.9万 - 项目类别:
Allosteric regulation of human cystathionine beta-synthase
人胱硫醚β-合酶的变构调节
- 批准号:
10381000 - 财政年份:2022
- 资助金额:
$ 20.9万 - 项目类别:
Structural basis for allosteric regulation of RyR1
RyR1 变构调节的结构基础
- 批准号:
10366087 - 财政年份:2021
- 资助金额:
$ 20.9万 - 项目类别: